Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-05-11 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Shareholders vote in favour of Alexion acquisition
Regulatory Filings Classification · 98% confidence The document is an RNS announcement (indicated by 'RNS Number : 2662Y') dated May 11, 2021. The core content reports the results of a shareholder vote regarding the acquisition of Alexion Pharmaceuticals. Specifically, it details the 'Resolution' and the 'Votes for'/'Votes against' breakdown, which is the official result of a shareholder vote at a general meeting. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions the acquisition (TAR) and references the circular (PSI), the primary purpose of this specific filing is to announce the outcome of the vote.
2021-05-11 English
IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON
Foreign Filer Report
2021-05-07 English
Imfinzi + tremelimumab showed survival in POSEIDON
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date (07 May 2021), indicating it is a regulatory announcement distributed via RNS (Regulatory News Service). The content details the positive results from the POSEIDON Phase III clinical trial for AstraZeneca's drug Imfinzi, focusing on survival benefits and safety profiles. This type of announcement, which releases key clinical trial data and business updates to the market, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a specific, non-standard announcement. Since it is a detailed announcement of clinical trial results, which often accompanies or precedes a formal earnings report, it fits best under the 'Earnings Release' category (ER) as it communicates key performance/development milestones, or potentially 'Regulatory Filings' (RNS) due to the RNS header. Given the detailed nature of the clinical data release, which is a major event for investors, ER is a strong candidate, but RNS is the most accurate category for a general regulatory news service release that isn't a standard financial report (10-K, IR, MRQ). However, looking at the definitions, 'ER' is for initial announcement of periodical financial results (key highlights only). This is a clinical trial result announcement, which is a major business update. Since it is explicitly distributed via RNS and doesn't fit perfectly into ER (which usually implies quarterly/periodical financial results), 'RNS' (Regulatory Filings) serves as the best general category for significant, non-standard regulatory news releases.
2021-05-07 English
425 Filing
Regulatory Filings
2021-05-07 English
425 Filing
Regulatory Filings
2021-05-06 English
425 Filing
Regulatory Filings
2021-05-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.